Protection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stress

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Huang, Xiaoping ^a   Wang, Xiao ^a   Lv, Yinghui ^a   Xu, Luli ^a   Lin, Junsheng ^a   Diao, Yong ^a  

^a HUAQIAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CARBON TETRACHLORIDE; HYALURONIC ACID; HYDROGEN PEROXIDE; HYDROXYPROLINE; KALLISTATIN; LAMININ; LIVER PROTECTIVE AGENT; MALONALDEHYDE; PROCOLLAGEN; PROCOLLAGEN TYPE 3; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; SMOOTH MUSCLE ACTIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COLLAGEN TYPE 3; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; DOSE RESPONSE; ENZYME ACTIVITY; FIBROGENESIS; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER FUNCTION; LIVER PROTECTION; MALE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PICHIA PASTORIS; PROTEIN EXPRESSION; RAT; STELLATE CELL; ANIMAL; BLOOD; CELL LINE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; HUMAN; INFLAMMATION; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PICHIA; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARBON TETRACHLORIDE; CELL LINE; COLLAGEN TYPE III; HEPATIC STELLATE CELLS; HUMANS; HYALURONIC ACID; HYDROGEN PEROXIDE; HYDROXYPROLINE; INFLAMMATION; LAMININ; LIVER; LIVER CIRRHOSIS; MALE; OXIDATIVE STRESS; PICHIA; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SERPINS;

EID: 84897805863     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088498     Document Type: Article

References (27)

1. Pellicoro A, Ramachandran P, Iredale JP (2012) Reversibility of liver fibrosis. Fibrogenesis Tissue Repair 5 Suppl 1: S26.
2. Friedman SL (2010) Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7: 425-436.
3. Liu Y, Bledsoe G, Hagiwara M, Shen B, Chao L, et al. (2012) Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol 303: F1230-1238.
4. Shen B, Hagiwara M, Yao YY, Chao L, Chao J (2008) Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 51: 1358-1365. (Pubitemid 351555950)
5. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, et al. (2005) Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 52: 1319-1324.
6. Gao L, Yin H, S. Smith R J, Chao L, Chao J (2008) Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 88: 1157-1166.
7. Chao J, Yin H, Yao YY, Shen B, Smith RS, Jr., et al. (2006) Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 17: 1201-1213. (Pubitemid 44975137)
8. Yin H, Gao L, Shen B, Chao L, Chao J (2010) Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension 56: 260-267.
9. Diao Y, Zhao XF, Lin JS, Wang QZ, Xu RA (2011) Protection of the liver against CCl4-induced injury by intramuscular electrotransfer of a kallistatin-encoding plasmid. World J Gastroenterol 17: 111-117.
10. Huang X, Wang X, Dong H, Zhao X, Li Z, et al. (2010) High level expression of recombinant human kallistatin in Pichia pastoris and its bioactivity. Chin J Biotech 26: 249-255.
11. Xu R, Harrison PM, Chen M, Li L, Tsui TY, et al. (2006) Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther 13: 1093-1100. (Pubitemid 43779184)
12. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, et al. (2012) Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proc Natl Acad Sci U S A 109: E1369-1376.
13. Kim HJ, Yu MH, Lee IS (2008) Inhibitory effects of methanol extract of plum (Prunus salicina L., cv. 'Soldam') fruits against benzo(alpha)pyrene- induced toxicity in mice. Food Chem Toxicol 46: 3407-3413.
14. Shaker ME, Salem HA, Shiha GE, Ibrahim TM (2011) Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. Fundam Clin Pharmacol 25: 248-257.
15. Itoh A, Isoda K, Kondoh M, Kawase M, Watari A, et al. (2010) Hepatoprotective effect of syringic acid and vanillic acid on CCl4-induced liver injury. Biol Pharm Bull 33: 983-987.
16. Guillaume M, Rodriguez-Vilarrupla A, Gracia-Sancho J, Rosado E, Mancini A, et al. (2013) Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. J Hepatol 58: 240-246.
17. Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, et al. (2011) The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One 6: e23218.
18. Kisseleva T, Brenner DA (2011) Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol 25: 305-317.
19. Cohen-Naftaly M, Friedman SL (2011) Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 4: 391-417.
20. Zhu H, Chao J, Kotak I, Guo D, Parikh SJ, et al. (2012) Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. Metabolism.
21. Hsieh J-L, Shen P-C, Shiau A-L, Jou I-M, Lee C-H, et al. (2009) Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther 20: 147-158.
22. Wang CR, Chen SY, Shiau AL, Wu CL, Jou IM, et al. (2007) Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol 34: 2171-2176.
23. Miao RQ, Chen V, Chao L, Chao J (2003) Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol 284: C1604-1613. (Pubitemid 36583402)
24. Miao RQ, Agata J, Chao L, Chao J (2002) Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 100: 3245-3252. (Pubitemid 35217074)
25. Diao Y, Ma J, Xiao WD, Luo J, Li XY, et al. (2007) Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kall istatin. World J Gastroenterol 13: 4615-4619. (Pubitemid 47455244)
26. Luo Q, Siconolfi-Baez L, Annamaneni P, Bielawski MT, Novikoff PM, et al. (2007) Altered protein expression at early-stage rat hepatic neoplasia. American Journal of Physiology-Gastrointestinal and Liver Physiology 292: G1272-G1282. (Pubitemid 47084666)
27. Chao J, Schmaier A, Chen LM, Yang Z, Chao L (1996) Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med 127: 612-620. (Pubitemid 26310340)